Sigma-Aldrich®
Lab & Production Materials

MilliporeSigma

Cell Marque™ Tissue Diagnostics

# ATRX Rabbit Polyclonal Antibody

## For use in neuropathology applications

Diffuse gliomas are classified based on histological and molecular features to achieve an integrated diagnosis. Molecular diagnostic markers include IDH mutation, 1p/19q co-deletion, and TP53 mutation. ATRX is a chromatin remodeling protein, and its mutation status may be used as a molecular diagnostic marker within the diffuse glioma classification algorithm. Anti-ATRX is used to identify mutant ATRX by a loss of ATRX expression in neoplastic cells when compared with internal positive controls (endothelial cells, glia, and neurons). Grade II/III astrocytoma classification includes IDH mutant, ATRX mutant, and 1p/19q retention, while grade II/III oligodendroglioma includes IDH mutant, ATRX wildtype, and 1p/19q co-deletion; p53 expression may also serve as an aid in diagnosis. ATRX mutation is frequently, but not always, mutually exclusive with 1p/19q co-deletion.[1-6]



Oligodendroglioma



Astrocytoma



Astrocytoma

### Ordering Information:

| Description | Cat No. |
|---|---|
| 0.1 mL concentrate | **485A-14** |
| 0.5 mL concentrate | **485A-15** |
| 1.0 mL concentrate | **485A-16** |
| 1.0 mL predilute ready-to-use | **485A-17** |
| 7.0 mL predilute ready-to-use | **485A-18** |

**Intended Use:**

This antibody is intended for *in vitro* diagnostic (IVD) use. ATRX Rabbit Polyclonal Antibody is intended for laboratory use in the detection of the ATRX protein in formalin-fixed, paraffin-embedded human tissue stained in qualitative immunohistochemistry (IHC) testing. The results using this product should be interpreted by a qualified pathologist in conjunction with the patient's relevant clinical history, other diagnostic tests and proper controls.

**Product Information:**

**Visualization:** Nuclear

**Controls:** Astrocytoma, Glioblastoma, Brain, Oligodendroglioma

**Dilution:** 1:50

**Associated Specialty:** Neuropathology

**References:**


1. Cancer Genome Atlas Research Network. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N Engl J Med. 2015 Jun 25;372(26):2481-98.
2. Reuss DE, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015 Jan;129(1):133-46.
3. Louis DN, et al. The 2016 World Health Organization Classifi cation of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016 Jun;131(6):803-20.
4. Ikemura M, et al. Utility of ATRX immunohistochemistry in diagnosis of adult diff use gliomas. Histopathology. 2016 Aug;69(2):260-7.
5. Yamamichi A, et al. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. Brain Tumor Pathol. 2018 Apr;35(2):106-113.
6. Wood MD, et al. Applications of molecular neuro-oncology - a review of diff use glioma integrated diagnosis and emerging molecular entities. Diagn Pathol. 2019 Apr 9;14(1):29.


The product is FDA Class 1 in the US. The product featured is not available in all countries.

Contact your local sales representative or distributor for details.


Toll Free: **800.665.7284**
Phone: **916.746.8900**
Fax: **916.746.8900**
Email: **service@cellmarque.com**
**www.cellmarque.com**

MilliporeSigma
400 Summit Drive
Burlington, MA 01803

**www.SigmaAldrich.com**





Lit. No. MS_FL8635EN Ver. 1.1 38559 05/2022